Wanbury Ltd - Stock Valuation and Financial Performance

BSE: 524212 | NSE: WANBURY | Pharmaceuticals & Drugs | Small Cap

Wanbury Share Price

145 3.50 2.47%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Wanbury

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Wanbury stock performance -

mw4me loader
P/E Ratio (SA):
20.46
Market Cap:
477.6 Cr.
52-wk low:
34.1
52-wk high:
177.4

Is Wanbury Ltd an attractive stock to invest in?

1. Is Wanbury Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Wanbury Ltd is a average quality company.

2. Is Wanbury Ltd undervalued or overvalued?

The key valuation ratios of Wanbury Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Wanbury Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Wanbury Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Wanbury:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Wanbury Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -17%5.5%7.4%46.9%-11.1%6%61.3%11.2%101.5%8.7%-
Value Creation
Index
NANANA2.4NANA3.4NA6.3NA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 441500423434371391367393511500569
Sales YoY Gr.-13.3%-15.3%2.5%-14.5%5.5%-6.1%6.8%30.2%-2.3%-
Adj EPS -32.6-1.1-3.324.9-13.9-10.42.5-4.811-2.97.1
YoY Gr.-NANANA-155.7%NANA-293.9%NA-126.5%-
BVPS (₹) -64.1-193-99.3-54.9-67.2-77.5-47.2-52.40.3-2.84.1
Adj Net
Profit
-65.2-2.2-6.657.8-32.9-24.66.2-11.935.8-9.523
Cash Flow from Ops. 49.180.143.243.432.529.744.116.740.519.8-
Debt/CF from Ops. 5.39.58.76.26.87.83.79.61.73.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 1.4%6.1%10.8%-2.3%
Adj EPS NANA-205.6%-126.5%
BVPSNANANA-1048.3%
Share Price 20.8% 46% 18.3% 293.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
376.50.74-39.82314.4-4.19.6-55.7374.11072.2
Op. Profit
Mgn %
6.98.67.94.3-18.23.6-5.94.36.44.811.6
Net Profit
Mgn %
-14.8-0.4-1.613.3-8.9-6.31.7-37-1.94.1
Debt to
Equity
-2-2-1.9-2.1-1.4-1.3-1.4-1.271.5-7.1-
Working Cap
Days
147295162159127748678849744
Cash Conv.
Cycle
21152-17-51-59-81-77-60-68-40

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 10.79%

Sales growth is good in last 4 quarters at 14.07%

Return on Equity has declined versus last 3 years average to 1.00%

Net Profit has been subdued in last 3 years -205.64%

Latest Financials - Wanbury Ltd.

Standalone Consolidated
TTM EPS (₹) 7.1 7.1
TTM Sales (₹ Cr.) 569 569
BVPS (₹.) 4.1 -3.7
Reserves (₹ Cr.) -19 -45
P/BV 35.76 -39.14
PE 20.46 20.47
From the Market
52 Week Low / High (₹) 34.06 / 177.40
All Time Low / High (₹) 0.85 / 267.00
Market Cap (₹ Cr.) 478
Equity (₹ Cr.) 32.8
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Wanbury:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *76.7676.7676.7676.7476.740.0076.7476.7476.7476.74
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales662250423434371391367393511500
Operating Expenses 621228391415439378389377479477
Manufacturing Costs43163134252229273132
Material Costs304119182197174196176221300303
Employee Cost 112408588877667647581
Other Costs 16354929715284117647361
Operating Profit 41213219-6813-22163223
Operating Profit Margin (%) 6.2%8.6%7.7%4.3%-18.3%3.4%-5.9%4.0%6.2%4.6%
Other Income 56190771246551
Interest 48193236314033232121
Depreciation 235910101010101112
Exceptional Items -2420000083076-1
Profit Before Tax -2674-762-32-2565-1281-10
Tax 3100000000
Profit After Tax -2703-762-32-2564-1381-10
PAT Margin (%) -40.8%1.3%-1.7%14.3%-8.6%-6.3%17.5%-3.2%15.9%-2.1%
Adjusted EPS (₹)-135.01.6-3.526.7-13.5-10.525.8-5.024.9-3.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund -166-168-175-127-159-184-118-1311-9
Share Capital 20202023242425253333
Reserves -186-188-195-151-183-208-143-156-31-42
Minority Interest0000000000
Debt354348322217182208124881313
Long Term Debt279270231154991231007200
Short Term Debt74789163838525161313
Trade Payables93998614083112121133179148
Others Liabilities 124116155178163145146191152144
Total Liabilities 405394386407268281274282345297

Fixed Assets

Gross Block310306326197199202203216227239
Accumulated Depreciation13614214510203039496072
Net Fixed Assets174164180186178172164167167167
CWIP 13191410109141122
Investments 0000000000
Inventories35343534131912255022
Trade Receivables103997585294451346368
Cash Equivalents 71279651712254
Others Assets73687583313116333834
Total Assets 405394386407268281274282345297

Cash Flow

(All Figures are in Crores.)
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 74404343323044174120
PBT -2674-762-32-2565-1281-10
Adjustment 3282348-374043-4133-4437
Changes in Working Capital 1313218261221-33-7
Tax Paid 0000-100-100
Cash Flow From Investing Activity -7-5-20-13-1-36481-9
Capex -12-5-21-15-3-5-8-41-13
Net Investments 0000000000
Others 4022127112-14
Cash Flow From Financing Activity -75-30-28-27-33-27-108-17-29-32
Net Proceeds from Shares 201200000500
Net Proceeds from Borrowing -34-1200000000
Interest Paid -44-21-23-16-7-11-11-7-15-17
Dividend Paid 0000000000
Others 04-17-11-27-15-97-11-63-15
Net Cash Flow -95-53-200713-21
PARTICULARSSep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)N/AN/AN/AN/AN/AN/AN/AN/A0N/A
ROCE (%)N/AN/AN/AN/AN/AN/AN/AN/A206.26N/A
Asset Turnover Ratio1.250.641.111.121.171.511.341.421.641.59
PAT to CFO Conversion(x)N/A13.33N/A0.69N/AN/A0.69N/A0.51N/A
Working Capital Days
Receivable Days501457366533247393547
Inventory Days20492928221416172626
Payable Days89294185209233181242210190197

Wanbury Ltd Stock News

Wanbury Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Wanbury on 28-Mar-2024 16:01 is ₹145.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Wanbury stood at ₹477.6.
The latest P/E ratio of Wanbury as of 28-Mar-2024 16:01 is 20.46.
The latest P/B ratio of Wanbury as of 28-Mar-2024 16:01 is 35.76.
The 52-week high of Wanbury is ₹177.4 and the 52-week low is ₹34.06.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wanbury is ₹569.2 ( Cr.) .

About Wanbury Ltd

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.

The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.

Product range of the company includes:

  • Coriminic table
  • Cpink table
  • Nock 2 tab
  • Senasof tab
  • Zevanuron
  • Rabiplus cap
  • Folinine
  • Cpink-s
  • Nuture
  • Adtrol 200mg

Milestones:

2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT.

2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s.

2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.

2002Pearl Organics got US FDA approval for Patalganga plant.

1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.

1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).

1992Pearl Organics established its first plant in Tarapur for manufacturing API’s.

1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.

1990Incorporated as Pearl Distributors Pvt

Achievements/ recognition:-

  • Wanbury ranks 47th as per ORG-IMS (Jan-2009) 
  • Cpink awarded “Best Brand Launch' by ORG IMS (06-07)  
  • Rabiplus awarded “Best Brand Launch' by ORG IMS (07-08) 
  • World's largest producer of Metformin
  • Fastest growing company amongst top 100 companies in the domestic market as per ORG IMS.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.